BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data

BrainStorm Cell Therapeutics Inc. BCLI, a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015. BrainStorm Cell Therapeutics BrainStorm's CEO Tony Fiorino, MD, PhD, commented "We are thrilled to have the opportunity to share our results at this prestigious venue, and we look forward to discussing these findings with the medical community." NurOwn® is an autologous cell therapy in which bone marrow-derived mesenchymal stem cells are expanded and then, under proprietary conditions, induced to secrete several neurotrophic factors known to promote neuronal survival. BrainStorm has completed two clinical trials of these neurotrophic factor-secreting mesenchymal stem cells in Israel, and is currently enrolling a randomized, double-blind, placebo-controlled phase 2 study at three centers in the United States. The presentation details are as follows: Poster: P2.059 "Autologous Transplantation of Mesenchymal Stem Cells Secreting Neurotrophic Factors (Nurown™) in ALS: Results of a Phase 2 Clinical Trial" Session Date/Time: Session P2, Tuesday April 21, 2015, 7:30am to 12:00pm (EDT) Location: Walter E. Washington Convention Center, Washington, DC